Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study.

Trial Profile

Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brentuximab vedotin (Primary)
  • Indications Anaplastic large cell lymphoma; Diffuse large B cell lymphoma; Haematological malignancies; Hodgkin's disease; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Seagen
  • Most Recent Events

    • 22 Jan 2016 According to Takeda Pharmaceutical media release, European Commission has approved a Type II variation for ADCETRIS (brentuximab vedotin) to include data on the retreatment of adult patients with relapsed or refractory (R/R) Hodgkin lymphoma or R/R systemic anaplastic large cell lymphoma (sALCL). EC decision followed the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in October 2015.
    • 14 May 2013 Preliminary data were previously reported at the 2011 American Society of Hematology (ASH) Annual Meeting and at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting, according to Seattle Genetics.
    • 14 May 2013 The US FDA accepted for filing a supplement to the Biologics License Application supporting the use of brentuximab vedotin for retreatment and extended duration based on the results of this study, according to a Seattle Genetics media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top